Archives

Ionis stock gains on data for HAE therapy (NASDAQ:IONS)

Evening pictures Ionis Pharmaceuticals (Nasdaq: ions(Amazon) announced Friday that its investigational treatment dondalorsen has achieved positive results in two late-stage trials for hereditary angioedema (HAE), a rare genetic disorder…

Ionis angioedema drug shows positive results in Phase 3 trial (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ:IONS) on Monday announced positive topline Phase 3 trial results for its donidalorsen drug candidate for hereditary angioedema (HAE). The Phase 3 OASIS-HAE study found donidalorsen met the primary endpoint of…